DEF 14A: Charles River Laboratories Sets Date for 2024 Annual Shareholder Meeting

Charles River Laboratories announces its 2024 Annual Meeting of Shareholders to be held on May 8, 2024, in Boston.

Summary

• Charles River Laboratories will hold its 2024 Annual Meeting of Shareholders on May 8, 2024, at 8:00 a.m. at the offices of Cooley LLP in Boston.
• Shareholders will vote on the election of eleven directors, an advisory resolution on executive compensation, and the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2024.
• A shareholder proposal will also be considered.
• The Board of Directors recommends voting for the election of each director, for the advisory vote on executive compensation, for the ratification of PricewaterhouseCoopers LLP, and against the shareholder proposal.
• The record date for determining shareholders entitled to notice of and to vote at the Annual Meeting was March 15, 2024.
• The proxy statement and annual report are available online at www.criver.com/annual2024.

Sentiment

Score: 7

Explanation: The document is primarily informational, outlining meeting details and voting recommendations. While it highlights some positive financial results, it also acknowledges challenges and risks, resulting in a moderately positive sentiment.

Positives

• Charles River shareholders provided strong majority support for our named executives compensation at our 2023 Annual Meeting of Shareholders (87.4% of shares voted in support of this matter).
• The company has a clawback policy on the recoupment of certain executive compensation in the event of an accounting restatement.
• The company has a commitment to ESG principles.
• The company has a code of business conduct and ethics.
• The company has an independent board committee chairs.
• The company has information security risk oversight by the Audit Committee.
• The company has corporate strategy and risk oversight by the Board.
• The company has a political contribution policy.
• The company has stock ownership requirements for officers and directors.

Negatives

• A shareholder proposal from PETA is recommended against by the board.
• The company voluntarily suspended planned future shipments of Cambodia non-human primates into the United States until such time that the Company and the USFWS could agree upon and implement additional procedures to reasonably ensure that non-human primates imported to the United States from Cambodia are purpose-bred.

Risks

• The company faces risks related to operational regulatory matters, such as quality control and data privacy.
• The company faces risks related to significant business decisions.
• The company faces risks related to Board succession planning, ethics practices, matters addressed in our Corporate Governance Guidelines, and other corporate governance issues.
• The company faces risks related to the NHP supply chain.

Future Outlook

The company is actively positioning itself to leverage its leadership position in non-clinical drug development and capitalize on opportunities when the demand environment improves.

Management Comments

• James C. Foster, Chair, President and Chief Executive Officer: 'Whether you plan to attend the Annual Meeting or not, it is important that your shares are represented.'
• The Board believes that Dr. Mackay is exceptionally qualified to continue to serve on the Board and that he brings a unique background that is critical to the overall experience of the Board.

Industry Context

The document highlights the importance of outsourced services in the pharmaceutical and biotechnology industries, particularly in early-stage research and development.

Comparison to Industry Standards

• The document benchmarks executive compensation against a peer group of 37 companies, including Abbott Laboratories, Gilead Sciences, Amgen Inc., and Thermo Fisher Scientific Inc.
• The company uses a regression model to analyze the competitiveness of executive compensation compared to the peer group.

Management Changes

Corporate Governance

Legal Proceedings

• The U.S. Department of Justice (DOJ) and the U.S. Fish & Wildlife Service (FWS) have commenced an investigation into the Company’s conduct regarding several shipments of non-human primates from Cambodia.
• The SEC recently announced a new investigation into our company's acquisition of monkeys from Asia.
• The FWS has also prevented our company from selling 1,269 monkeys to laboratories because the company couldn't prove they had been imported legally.

Stakeholder Impact

• The company's actions and policies impact shareholders, employees, customers, and the broader scientific community.
• The company's commitment to ethical practices and animal welfare is crucial for maintaining stakeholder trust and supporting scientific advancements.

Next Steps

• Shareholders are urged to vote their shares promptly.
• The Board of Directors and the Compensation Committee will carefully review and consider the voting results when making future decisions regarding the executive compensation program.
• The company will continue to engage with shareholders on various corporate governance topics.

Key Dates

Keywords

Annual Meeting, Shareholders, Proxy Statement, Board of Directors, Executive Compensation, Director Election, PricewaterhouseCoopers, Corporate Governance, Risk Oversight, ESG, Non-human primates